Hypertrophic Cardiomyopathy Symptom Release by BX1514M

Summary

Hypertrophic cardiomyopathy (HCM) is the most frequent genetic cardiac disease characterized by an asymmetric hypertrophic. In two third of patients, an obstruction to blood ejection is observed within the left ventricle which is named left ventricular outflow tract obstruction (LVOTO). This phenomenon can occur at rest or during exercise and is associated with symptoms such as dyspnea, dizziness or chest pain that can significantly limit day life adaptation. To now, medical or interventional treatments such as betablocacker, calcium blockers or septal alcoholisation or surgery present with a limited efficiency. Recent studies from investigators group revealed new concepts about the role of venous return to the LVOTO. Therefore the investigators hypothesis that BX1514M generating a venous vascular constriction, could improve symptoms of HCM patients by reducing LVOTO.

Timeline

Start

2015-10-07

Primary completion

2016-07-06

Completion

2016-07-06

Publications

• Results Lafitte S, Peyrou J, Reynaud A, Dijos M, Cornolle C, Roudaut R, Touche C, Ritter P, Reant P. Midodrine hydrochloride and unexpected improvement in hypertrophic cardiomyopathy symptoms. Arch Cardiovasc Dis. 2016 Mar;109(3):223-5. doi: 10.1016/j.acvd.2015.11.005. Epub 2016 Feb 15. No abstract available.

Drugs

Indications